Welcome to our dedicated page for VolitionRX news (Ticker: VNRX), a resource for investors and traders seeking the latest updates and insights on VolitionRX stock.
VolitionRx Limited (VNRX) is a U.S.-based epigenetics company at the forefront of developing non-invasive blood tests for early detection and monitoring of life-altering diseases, including various cancers. By leveraging their proprietary Nucleosomics™ platform, VolitionRx is pioneering diagnostic tests that identify and measure nucleosomes in the bloodstream, indicating the presence of disease.
The company's goal is to make these blood tests as commonplace and straightforward as current diabetic and cholesterol tests. VolitionRx operates through subsidiaries, with its primary research and development activities based in Belgium. The company also has offices in the U.S., London, and Singapore, focusing on bringing revolutionary diagnostic products to market across Europe, the U.S., and globally.
VolitionRx's innovative product portfolio includes the Nu.Q® NETs test and the Nu.Q® Vet Cancer Test. The company has recently expanded into veterinary diagnostics with the Nu.Q® Vet Cancer Test, now available in Japan through a partnership with Fujifilm Vet Systems and in the U.S. and Europe through Antech Diagnostics. This expansion aims to provide veterinarians with simple, cost-effective tools for early cancer detection in dogs.
In 2023, VolitionRx achieved several milestones, including significant partnerships and the commercialization of its veterinary products. The company also made strides in its human diagnostics pipeline, with plans to advance its regulatory pathway with the U.S. FDA and large-scale clinical studies scheduled for publication.
VolitionRx remains focused on advancing the science of epigenetics to improve patient outcomes. The company aims to achieve cash flow neutrality by 2025 through a mix of revenue growth, milestone payments from licensing agreements, and cost reduction measures.
For more information, visit www.volitionrx.com, or follow them on Twitter, LinkedIn, and Facebook.
VolitionRx (NYSE AMERICAN: VNRX) has appointed LifeSci Advisors (LSA) as its investor relations consultants. The company, which specializes in epigenetics, made this announcement following significant progress in 2024, including the launch of Nu.Q® Vet Cancer Test in the U.S. and Europe through Antech.
The company plans to participate in the 14th Annual LifeSci Partners Corporate Access Event on January 15th, 2025, at the Beacon Grand Hotel in San Francisco, coinciding with the J.P. Morgan Health Care Conference. Volition anticipates multiple financial and value-creating operating milestones in human applications for both cancer and sepsis in 2025.
VolitionRx (NYSE AMERICAN: VNRX) announced results from an 800-patient study showing its Nu.Q® Cancer Test can differentiate between malignant and benign pulmonary nodules found by Low Dose CT (LDCT) scan in lung cancer screening. The study, led by Professor Jin-Shing Chen at National Taiwan University Hospital, revealed that a panel of two Nu.Q® nucleosome quantification assays achieved 92% diagnostic sensitivity and 89% Positive Predictive Value when combined with LDCT screening.
A 500-patient validation study in a real-world setting is planned to begin this year, with completion expected in 2025. If successful, the test could be included in Taiwan's National Lung Cancer Screening Program, potentially reducing unnecessary biopsies and surgeries for patients with benign nodules.
VolitionRx (NYSE AMERICAN: VNRX) has announced a registered direct offering expected to raise up to $1.9 million in gross proceeds. The offering includes the sale of 445,648 shares to company insiders at $0.5722 per share, and 2,857,389 shares with warrants to other investors at the same price.
The offering includes Form A warrants to purchase up to 2,857,389 shares at $0.5722 per share and Form B warrants for up to 1,428,693 shares at $0.71525 per share, both exercisable immediately with a 5-year expiration. If fully exercised, the warrants could generate additional gross proceeds of approximately $2.7 million.
The company plans to use the proceeds for research, product development, clinical studies, commercialization, and working capital.
VolitionRx (VNRX) reported strong Q3 2024 results, with revenue reaching $475,000, up 187% year-over-year. Year-to-date revenue hit $1 million, a 96% increase from the previous year. The company sold over 110,000 Nu.Q® Vet Cancer Tests in the first three quarters of 2024, with the test now available in 17 countries. Cash position stood at $5.4 million as of September 30, with an additional $2.2 million in non-dilutive funding secured from the Walloon Region, Belgium. The company aims to achieve cash neutrality in 2025.
VolitionRx (NYSE AMERICAN: VNRX) has announced a conference call scheduled for Friday, November 15 at 8:30 a.m. U.S. Eastern Time to discuss their third quarter 2024 financial and operating results, along with a business update. The call will be hosted by key executives including Louise Batchelor, Cameron Reynolds, Terig Hughes, Dr. Tom Butera, and Dr. Andrew Retter. A live audio webcast will be available, and a telephone replay will be accessible until November 29, 2024.
VolitionRx (NYSE AMERICAN: VNRX) has appointed Timothy Still as Chairman of its board of directors, effective November 06, 2024. Still brings over 35 years of experience in medical diagnostics, devices, and digital health. He previously served as President and CEO of Sense Biodetection and held leadership positions at various medical technology companies. His most recent role was at TSTILL Enterprises as Chairman and CEO, while also serving as an Operating Partner with REVIVAL Healthcare. Still holds an MBA from USC and a BS from UC Davis. The appointment comes at what the company describes as a pivotal time in its development of epigenetic technology for disease detection and monitoring.
VolitionRx (NYSE AMERICAN: VNRX) has published findings from three large, independent studies conducted in France, Germany, and the Netherlands, involving over 3,000 sepsis patients. The studies demonstrate that their Nu.Q® NETs test could predict patients at higher risk of deteriorating from sepsis by measuring levels of circulating H3.1 nucleosomes in the bloodstream. Research shows that elevated H3.1 levels are associated with increased risk of mortality, renal failure, respiratory failure, multi-organ failure, and septic shock. The company is currently seeking to commercialize Nu.Q® NETs and using these study findings to support licensing discussions with industry stakeholders.
VolitionRx (NYSE AMERICAN: VNRX) is participating in a webinar hosted by Edison Group to discuss new data on the potential use of Nu.Q® NETs in sepsis management. The data, presented at ESICM LIVES 2024, includes three independent studies involving over 3000 patients and more than 14,000 patient samples. The webinar, scheduled for October 21, 2024, at 10:00 AM ET, will feature updates from Volition's Chief Medical Officer and Chief Commercial Officer.
The presentation will focus on the role of H3.1 nucleosomes in NETosis, the implications of elevated H3.1 levels in sepsis patients, and the potential of Nu.Q® NETs biomarker to predict organ failure. Volition's Nu.Q® NETs technology quantifies circulating H3.1 nucleosomes in the bloodstream, serving as a surrogate marker for Neutrophil Extracellular Traps (NETs). The company aims to develop simple, cost-effective blood tests for diagnosing and monitoring various diseases, including cancer, in both humans and animals.
VolitionRx (NYSE AMERICAN: VNRX) is hosting a symposium at ESICM Lives 2024 in Barcelona on October 7, 2024. The session, titled 'NETs: Casting a new light on sepsis management', will feature experts presenting findings from large, independent studies on using Nu.Q® NETs to enhance sepsis management.
Professor Djillali Annane, chair of the symposium, highlights the potential of Nu.Q® NETs H3.1 assay in clinical practice for sepsis management. The symposium will explore the role of H3.1 nucleosomes in NETosis, the clinical utility of H3.1 in recent large-scale studies, and how Nu.Q® NETs biomarker could predict organ failure.
Nu.Q® NETs is Volition's technology that quantifies circulating H3.1 nucleosomes in the bloodstream, a surrogate marker for Neutrophil Extracellular Traps (NETs). Elevated levels of NETs can lead to tissue damage, sepsis, organ failure, and death.
VolitionRx (NYSE AMERICAN: VNRX) has appointed Dr. Ethel Rubin as an independent director to its board, effective September 30, 2024. Dr. Rubin, with over 20 years of experience in the life sciences sector, will also serve on the Audit and Compensation Committees. Her extensive background includes leadership roles at BioFortis, CSA Medical, Medtronic, and currently as Head of Ventures at BioHealth Innovation.
Guy Innes, Interim Chair of Volition, highlighted Dr. Rubin's vast knowledge of the life sciences industry and her contribution to launching over 25 commercial products. Dr. Rubin expressed excitement about joining Volition, noting the potential of the company's Nu.Q® technology in both animal and human health sectors, particularly for early detection and monitoring of diseases like cancer and sepsis.
FAQ
What is the current stock price of VolitionRX (VNRX)?
What is the market cap of VolitionRX (VNRX)?
What does VolitionRx Limited do?
Where is VolitionRx Limited based?
What is the Nu.Q® Vet Cancer Test?
What are VolitionRx's recent achievements?
What is the Nucleosomics™ platform?
How is VolitionRx planning to achieve cash flow neutrality by 2025?
How can I get more information about VolitionRx?
What diseases does VolitionRx target with its tests?
What is the significance of VolitionRx's partnership with Fujifilm Vet Systems?
What upcoming milestones does VolitionRx expect?
